Cipla Announces Closure Of U.S. FDA Inspection At Bengaluru Facility  
An employee arranges medicine bottles during the manufacture of pharmaceuticals (Photographer: Akos Stiller/Bloomberg)

Cipla Announces Closure Of U.S. FDA Inspection At Bengaluru Facility  

Bookmark

Cipla Ltd. today announced the closure of inspection by the U.S. health regulator at the company's API manufacturing facility in Bengaluru.

"Following the inspection by the United States Food and Drug Administration at the company's API manufacturing facility in Virgonagar, Bengaluru, from July 15-19, 2019, the company has received the Establishment Inspection Report, indicating closure of the inspection," the company said in a filing to the BSE.

The company had earlier said that U.S. FDA issued seven observations after conducting a routine 'Current Goof Manufacturing Practice inspection' at Cipla's API manufacturing facility in Virgonangar, Bengaluru.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.